Sanofi reported 3Q19 Synvisc revenue of €73 million (USD $82 million), +1.4% vs. 3Q18.
- Sanofi’s U.S. viscosupplement sales rebounded somewhat after 2Q19, in which they were down double-digits year over year
- Continued strength in emerging markets offset U.S. losses, bringing positive growth for Synvisc for the first time in 2019
- ORTHOWORLD projects Sanofi full year 2019 Synvisc revenue of $356.1 million, +1.3% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $82.0 | $80.9 | $1.1 | 1.4% | 
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $256.2 | $260.7 | ($4.5) | (1.7%) | 
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $56.2 | $57.3 | ($1.1) | (2%) | 
| Ex-US | $25.8 | $23.6 | $2.2 | 9.5% | 
| Europe | $5.6 | $5.6 | $0.0 | 0% | 
| Emerging Markets | $15.7 | $14.6 | $1.1 | 7.7% | 
| Rest of World | $4.5 | $3.4 | $1.1 | 33.3% | 
| Total | $82.0 | $80.9 | $1.1 | 1.4% | 
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Sanofi reported 3Q19 Synvisc revenue of €73 million (USD $82 million), +1.4% vs. 3Q18.
 Sanofi’s U.S. viscosupplement sales rebounded somewhat after 2Q19, in which they were down double-digits year over year
 Continued strength in emerging markets offset U.S. losses, bringing positive growth for Synvisc for the first time in 2019
 ...
Sanofi reported 3Q19 Synvisc revenue of €73 million (USD $82 million), +1.4% vs. 3Q18.
- Sanofi’s U.S. viscosupplement sales rebounded somewhat after 2Q19, in which they were down double-digits year over year
- Continued strength in emerging markets offset U.S. losses, bringing positive growth for Synvisc for the first time in 2019
- ORTHOWORLD projects Sanofi full year 2019 Synvisc revenue of $356.1 million, +1.3% vs. 2018
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $82.0 | $80.9 | $1.1 | 1.4% | 
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $256.2 | $260.7 | ($4.5) | (1.7%) | 
Geographic Sales
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $56.2 | $57.3 | ($1.1) | (2%) | 
| Ex-US | $25.8 | $23.6 | $2.2 | 9.5% | 
| Europe | $5.6 | $5.6 | $0.0 | 0% | 
| Emerging Markets | $15.7 | $14.6 | $1.1 | 7.7% | 
| Rest of World | $4.5 | $3.4 | $1.1 | 33.3% | 
| Total | $82.0 | $80.9 | $1.1 | 1.4% | 
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.






